|
Peptide-specific
(tetramer positive) CD8 T cells from PBMCs analyzed ex vivoa.
|
Patients
|
Antigen
|
bFold
T cell expansion following vaccination (range)
|
cMean
% of CD28 negative T cells before vaccination
± standard deviation
|
|
Immune
responders
|
Melan-A
|
9.2 (2.3-24.0)
|
23 ± 25
|
|
Influenza
|
6.7 (2.7-13.0)
|
23 ± 23
|
|
Non-responders
|
Melan-A
|
1.1 (0.0-2.0)
|
6 ± 5
|
|
Influenza
|
1.2 (0.0-2.0)
|
8 ± 8
|
aPBMCs were stained ex vivo with fluorescent
HLA-A2/peptide tetramers, and CD8- and CD28-specific monoclonal
antibodies (as for Figure 1). 12 patients responded to Melan-A
and 9 patients to influenza peptides. 38 patients were evaluable
for changes in the percentage of tetramer positive T cells before
vs. after vaccination, and 23/31 patients (Melan-A/influenza)
for CD28 negative T cells before vaccination.
bThe percentage of Melan-A and influenza tetramer positive
T cells was determined, and the value after vaccination divided
by that prior to vaccination for each patient. Based on earlier
results, patients were classified as immune responders if they
had a >2-fold increase in the percentage of Melan-A- or influenza
peptide-specific T cells following vaccination, a downregulation
of CD45RA and/or CD28 by more than 20% of peptide-specific T cells,
and/or a >2-fold increase in IFN-gamma Elispots.
cShown are the percentages of CD28 negative cells among
peptide-specific T cells before vaccination. The differences between
immune responders and non-responders were statistically significant
(P<0.01 for Melan-A-specific T cells, P<0.005
for influenza-specific T cells).
Correction:
The sentence "The differences between immune responders and non-responders
were statistically significant (P<0.01 for Melan-A-specific
T cells, P<0.005 for influenza-specific T cells)" refers
to the comparison of the mean % of CD28 negative T cells before
vaccination among Melan-A- and influenza-specific cells, respectively
. Originally this sentence was at the end of footnote a instead
of footnote c.
|
